Role of Biosynthesis and Catabolism of Neurotransmitters in Drug Discovery for Anxiety and Depression
- PMID: 39075953
- DOI: 10.2174/0113816128309913240704095334
Role of Biosynthesis and Catabolism of Neurotransmitters in Drug Discovery for Anxiety and Depression
Abstract
The purpose of this review is to correlate the probable causes of anxiety disorders with the imbalance of neurotransmitters in the brain and also highlight the drugs for these mental disorders that have been discovered based on the biosynthesis and catabolism of these brain chemicals. Peer-reviewed journal's articles, news and books published in English between 1997 and 2023 describing the role of neurotransmitters in anxiety disorders were searched in Google Scholar, Research Gate and PubMed databases. The contents were carefully analyzed by the authors and understood and compiled to build a concise perspective on the role of biosynthesis and catabolism of neurotransmitters in anxiety and depression. Anxiety disorders are reported to be common patterns of psychological symptoms that impact multiple areas of life. Anxiety and depression are prevalent worldwide and are significantly contributing towards the global health burden. Genetic determinants are believed to play an important role in these disorders. According to modern medicine, one of the most important aspects that is known to be crucial for these disorders is the imbalance of neurotransmitters in the brain. The biosynthesis and catabolism of neurotransmitters have been extensively targeted for innovative drug discovery approaches at various steps that have led to the discovery of many drugs for these psychological disorders. The biosynthetic and catabolic reaction cycles of neurotransmitters and the discovery of drugs based on these hypotheses are discussed. To the best of the authors' knowledge, this review compiles already known descriptive knowledge on "relation of neurotransmitter imbalance with anxiety disorders" in a precise way that will provide readers with an overview of the vast literature.
Keywords: Anxiety disorders; biosynthesis; catabolism; depression; drug discovery.; neurotransmitters.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Translational Studies in the Complex Role of Neurotransmitter Systems in Anxiety and Anxiety Disorders.Adv Exp Med Biol. 2020;1191:121-140. doi: 10.1007/978-981-32-9705-0_8. Adv Exp Med Biol. 2020. PMID: 32002926 Review.
-
Neuropsychiatric Properties of the ACE2/Ang-(1-7)/Mas Pathway: A Brief Review.Protein Pept Lett. 2020;27(6):476-483. doi: 10.2174/0929866527666191223143230. Protein Pept Lett. 2020. PMID: 31868143 Review.
-
The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders.Expert Opin Ther Targets. 2005 Aug;9(4):651-84. doi: 10.1517/14728222.9.4.651. Expert Opin Ther Targets. 2005. PMID: 16083336 Review.
-
Xiaochaihutang attenuates depressive/anxiety-like behaviors of social isolation-reared mice by regulating monoaminergic system, neurogenesis and BDNF expression.J Ethnopharmacol. 2017 Aug 17;208:94-104. doi: 10.1016/j.jep.2017.07.005. Epub 2017 Jul 5. J Ethnopharmacol. 2017. PMID: 28687505
-
Sleep patterns in depression and anxiety: theory and pharmacological effects.J Psychosom Res. 1994;38 Suppl 1:125-39. doi: 10.1016/0022-3999(94)90143-0. J Psychosom Res. 1994. PMID: 7799244 Review.
References
-
- Bhatt N.V.; Baker M.J.; Jain V.B.; Anxiety Disorders. Available from: https://emedicine.medscape.com/article/286227- overview2019
-
- Vahia VN. American Psychiatric Association. Cautionary statement for forensic use of DSM-5. Diagnostic and statistical manual of mental disorders. 2013. - DOI
-
- Santomauro D.F.; Mantilla Herrera A.M.; Shadid J.; Zheng P.; Ashbaugh C.; Pigott D.M.; Abbafati C.; Adolph C.; Amlag J.O.; Aravkin A.Y.; Bang-Jensen B.L.; Bertolacci G.J.; Bloom S.S.; Castellano R.; Castro E.; Chakrabarti S.; Chattopadhyay J.; Cogen R.M.; Collins J.K.; Dai X.; Dangel W.J.; Dapper C.; Deen A.; Erickson M.; Ewald S.B.; Flaxman A.D.; Frostad J.J.; Fullman N.; Giles J.R.; Giref A.Z.; Guo G.; He J.; Helak M.; Hulland E.N.; Idrisov B.; Lindstrom A.; Linebarger E.; Lotufo P.A.; Lozano R.; Magistro B.; Malta D.C.; Månsson J.C.; Marinho F.; Mokdad A.H.; Monasta L.; Naik P.; Nomura S.; O’Halloran J.K.; Ostroff S.M.; Pasovic M.; Penberthy L.; Reiner R.C.; Reinke G.; Ribeiro A.L.P.; Sholokhov A.; Sorensen R.J.D.; Varavikova E.; Vo A.T.; Walcott R.; Watson S.; Wiysonge C.S.; Zigler B.; Hay S.I.; Vos T.; Murray C.J.L.; Whiteford H.A.; Ferrari A.J.; Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet 2021,398(10312),1700-1712 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical